SAFE vs. Convertible Note: What Pre-Seed Founders Need to Understand Before They Sign

The Default Is a SAFE — Here’s Why That’s Not Always Right

Y Combinator introduced the SAFE — Simple Agreement for Future Equity — in late 2013, and it spread fast. YC’s own documentation notes that it has since been used by almost all YC startups and countless non-YC startups as the primary instrument for early-stage fundraising. A decade later, “SAFE” has become synonymous with pre-seed financing the same way “Kleenex” became synonymous with tissue. The problem with synonyms is that people stop reading the label.

The SAFE is not debt. That distinction matters more than founders typically realize. A convertible note is a promissory note — it creates a legal obligation to repay principal and interest. A SAFE creates no such obligation. It is a contractual right to receive equity when a triggering event occurs (typically a priced round, acquisition, or dissolution), with no maturity date and no interest accrual. The SAFE replaced convertible notes in large part because, as Wyrick Robbins observed, everyone understood that startups couldn’t realistically repay convertible notes if a priced round never materialized — the debt structure was a legal fiction that added complexity without substance.

But that origin story is Silicon Valley’s origin story. Outside that ecosystem, the convertible note never went away. In New York and Boston, practitioners report that convertible notes remain common — a comparison of the two instruments is often the first step for East Coast founders whose investors prefer notes. In industries and regions where investors come from debt-oriented backgrounds, SAFEs can feel less familiar than notes — which applies to most of the country outside a few zip codes. If your lead investor cuts their teeth doing debt deals, handing them a SAFE may create friction that has nothing to do with your company’s fundamentals.

How the SAFE Works: Cap, Discount, and the Post-Money Math That Changed Everything

The original SAFE was designed as a bridge — a lightweight instrument to tide a startup over until a priced Series A. By 2018 that assumption no longer held. Seed rounds had grown large enough to be destinations in their own right, not just waiting rooms. YC acknowledged the shift directly: early-stage fundraising had evolved, and startups were raising much larger amounts of money as a first seed round of financing. The 2018 revision created the post-money SAFE — and the mechanical change was not cosmetic.

The core benefit of the post-money structure is arithmetic certainty. A post-money SAFE lets both the investor and the founder calculate immediately and precisely how much ownership of the company has been sold at the moment of signing. The formula is straightforward: a $500,000 investment at a $5,000,000 post-money valuation cap locks in exactly 10% ownership. That percentage is fixed and known before anyone has raised another dollar.

YC now offers four standard variants: a valuation cap only, a discount only, an uncapped note with a most-favored-nation clause, and an optional pro-rata side letter. The cap-only variant has become the clear market default — appearing in approximately 81% of SAFE deals by 2025, up from 76% the prior year, according to Carta’s State of Private Markets data. The MFN variant serves a specific purpose: if the company later issues a convertible instrument to another investor on more favorable terms, the MFN clause automatically adjusts the earlier investor’s terms to match. It functions as a backstop for investors willing to forgo a cap in exchange for that protection.

The Dilution Shift: Pre-Money vs. Post-Money

The structural change that catches founders off guard is how dilution now falls. Under pre-money SAFEs, multiple investors shared the dilution collectively — the pool of SAFE holders converted into equity together, and each one’s final ownership depended on who else was in the pool. Under post-money SAFEs, each investor is guaranteed their fixed ownership percentage as if no other SAFEs exist. That guarantee has a cost: every new SAFE issued dilutes only the founders, not existing SAFE holders.

The numbers make this concrete. Take three investors — Alice, Bob, and Charles — each putting in $1,000,000 against the same $10,000,000 cap. Under pre-money SAFEs, total founder dilution runs approximately 25% — reflecting that option pool expansion typically happens pre-conversion and is shared across holders. Under post-money SAFEs, each investor locks in 10% independently, producing 30% total founder dilution from the identical dollar amount. The post-money structure trades collective ambiguity for individual certainty — and founders absorb the difference.

How Convertible Notes Work: Interest, Maturity, and What Happens When Neither Side Converts

Unlike a SAFE, a convertible note is real debt. It accrues interest — typically between 3% and 8% annually — and it has a maturity date, usually 18 to 24 months from issuance, by which something is supposed to happen. That “something” is almost always a qualified financing round, but the note’s debt structure means a qualified financing isn’t the only possible outcome. Three others exist, and understanding them is what separates founders who use convertible notes intentionally from those who stumble into a structuring problem.

The interest mechanic also changes the conversion math in a way SAFE holders don’t face. When a convertible note converts at a qualified financing, the investor doesn’t just convert the principal — accrued interest converts too. On a $250,000 note at 6% annually held for 18 months, that’s roughly $22,500 in additional principal converting into equity. The discount and valuation cap already create dilution beyond what the raw dollar amount suggests; the interest accrual compounds it further. For founders running dilution models before closing a note round, that interest line item needs to be in the spreadsheet.

What Happens at Maturity

When a convertible note hits its maturity date without a qualified financing, the note agreement typically provides three paths: the investor can convert into equity at the valuation cap, the company can repay the principal plus accrued interest in cash, or the parties can extend the maturity date. In practice, extension is by far the most common outcome. The reason is straightforward: investors in convertible note rounds are not in the lending business. Their business model is taking equity stakes in startups, not collecting interest payments. Demanding cash repayment from a pre-revenue company that hasn’t yet closed a Series A is almost always self-defeating — it would likely bankrupt the company and leave the investor with nothing.

The reputational brake matters too. Startup investing is a small world, and pursuing legal action against a struggling founder damages an investor’s standing in an ecosystem that runs on deal flow and referrals. The economic logic and the social logic both push toward extension.

The practical structuring rule is simple: the maturity date is not a formality. A company whose realistic Series A timeline is 20 months should not close a convertible note with an 18-month maturity. The buffer needs to account for a fundraise that takes longer than expected, a market that closes temporarily, or a pivot that resets the clock. Negotiate for 24 months where you can — and if an investor pushes for 18, understand that you’re accepting a deadline you’ll likely need to renegotiate. That renegotiation is usually fine, but it’s a leverage event the investor controls, not you.

Valuation Cap and Discount: How Each Instrument Determines Your Actual Dilution

Every SAFE and convertible note converts into equity using one of two pricing mechanics — a valuation cap, a discount rate, or both. Getting these formulas wrong is how founders hand away far more of their company than they intended.

The cap formula is straightforward: divide the cap amount by the company’s fully-diluted share count at the time of conversion. A $10M cap against a capitalization of 1,000,000 shares produces a conversion price of $10 per share. The discount formula is equally direct: multiply the price paid by Series A investors by (1 minus the discount percentage). If new investors pay $1.00 per share and the SAFE carries a 20% discount, the SAFE converts at $0.80 per share — meaning the early investor receives 25% more shares than the new investor for the same dollar invested. A $500,000 SAFE at that $0.80 price issues 625,000 shares, compared to the 500,000 shares a non-discounted investor would receive at $1.00.

When a SAFE carries both a cap and a discount, the investor receives whichever calculation yields more shares — the two mechanics are not additive. That “more favorable of” rule matters enormously when the Series A valuation is high. Suppose the cap is $10M and the discount is 20%, but the Series A closes at a $50M pre-money valuation. The discount converts at $4.00 per share ($5.00 × 0.80). The cap converts at $1.00 per share ($10M ÷ 10,000,000 shares). The cap wins — and it produces four times more shares than the discount would have. The higher the Series A valuation climbs above the cap, the more punishing the cap becomes relative to any reasonable discount rate.

This is the mechanics problem that compounds across multiple SAFE rounds: each instrument sits off the visible cap table until a priced round forces conversion, and by that point the negotiating window has closed. Modeling your full dilution picture — all outstanding SAFEs converted at their respective caps and discounts — before issuing new instruments is the only way to maintain actual control of where your cap table lands at Series A.

When to Use Which: Geography, Investor Type, and What Founders Control

The “SAFE vs. note” question is partly a legal and financial question, and partly a question of who you are raising from and where they are located. Both answers matter.

SAFEs now dominate pre-seed rounds on major cap table platforms — Carta’s State of Private Markets data has tracked figures approaching 90% for Silicon Valley pre-seed — with the post-money cap-only SAFE functioning as the near-universal standard in that market. That concentration is not replicated nationally: New York and Boston have stronger convertible note cultures than the Bay Area, and the note remains common wherever investors come from debt-oriented backgrounds. The instrument that closes fastest in San Francisco may generate friction in a Boston office. If your target investors are outside the Valley, asking which instrument they prefer is not a negotiating concession — it is basic diligence.

Investor type creates equally strong preferences. Family offices typically want documented terms, interest accrual, and maturity dates that match their existing investment frameworks. A SAFE can feel structurally foreign to an investor whose portfolio is built around instruments with defined repayment expectations. Most institutional VCs are agnostic at pre-seed, but at seed stage many have template term sheets built around convertible notes and may treat SAFEs as unnecessary friction to their internal process. Angel investors and accelerators, by contrast, largely standardized on the SAFE precisely because it is fast and cheap — legal fees for a SAFE run under $2,000, compared to $2,000–$5,000 for a full convertible note package.

One thing founders do not trade away with either instrument: board control. Neither SAFEs nor convertible notes carry voting rights or board representation before conversion. Regardless of which instrument you issue, you retain full governance control until a priced equity round converts those instruments into stock. The choice between a SAFE and a note affects your economics and your investor relationship — not your seat at the table.